The aim of the study is to investigate the effectivity of visible light in combination with waterfiltered infrared in treating acne papulopustulosa. The reduction of inflammatory and non-inflammatory lesions within 8 weeks will be measured and compared with the standard treatment with Adapalene.

Condition	Intervention	Phase
Acne Papulopustulosa	Drug: Differin Gel	Phase IV

Ages Eligible for Study:  14 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Mild to moderate acne papulopustulosa according to Burton Scale Stage 3 to 4
• At least 5 inflammatory and 5 non-inflammatory lesions in the face
• Age >= 14 years

Exclusion Criteria:

• pregnant and nursing women
• Antiandrogen therapy
• therapy with antibiotics within the last 4 weeks
• therapy with retinoids within the last 6 months
• natural or artificial UV-therapy within the last 4 weeks
• severe acne papulopustulosa according to Burton Scale 5 or 6
• Severe systemic condition
• Secondary acne

Please refer to this study by ClinicalTrials.gov identifier  NCT00237978

Roland Aschoff, MD      0049-351-458  Ext. 2007    Roland.Aschoff@mailbox.tu-dresden.de

Germany, Sachsen
      Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden,  Sachsen,  01307,  Germany

Study chairs or principal investigators

Roland Aschoff, MD,  Principal Investigator,  Technische Universität Dresden, Fetscher Str. 74, 01307 Dresden, Germany   

Study ID Numbers:  Akne02
Last Updated:  December 8, 2005
Record first received:  October 12, 2005
ClinicalTrials.gov Identifier:  NCT00237978
Health Authority: Germany: Federal Institute for Drugs and Medicinal Devices
ClinicalTrials.gov processed this record on 2006-01-10